EpiPen emergency allergy shot in short supply, FDA says

FDA on Wednesday said the EpiPen emergency treatment for allergic reactions is in short supply in the United States because of manufacturing delays. Mylan, which sells EpiPens that are manufactured at a Pfizer plant, said some pharmacies lacked supply, but patients could find the drug at other pharmacies.

FDA on Wednesday said the EpiPen emergency treatment for allergic reactions is in short supply in the United States because of manufacturing delays. Mylan, which sells EpiPens that are manufactured at a Pfizer plant, said some pharmacies lacked supply, but patients could find the drug at other pharmacies. Pfizer said it was overcoming the manufacturing problems, saying it was increasing production. "FDA anticipates the EpiPen shortage to be short-term," the agency said in a statement. The shortage classification by FDA follows the request Monday by the Food Allergy Research and Education patient group for action to address the issue. EpiPens are made at a plant in Brentwood, MO, that received a warning letter from FDA last year for violations of good manufacturing practices. The letter said Pfizer's Meridian Medical Technologies division had received hundreds of complaints that EpiPen failed to operate during life-threatening emergencies, including some in which patients subsequently died.

Ad Position
Bottom Center Aligned